Skip to main content

Table 2 Risk of bias in included trials

From: A systematic review with attempted network meta-analysis of asthma therapy recommended for five to eighteen year olds in GINA steps three and four

Study ID[ref]

1

[19]

2

[20]

3

[21]

4

[22]

5

[23]

6

[24]

7

[25]

8

[26]

9

[7]

10

[9]

11

[27]

12

[28]

13

[29]

14

[30]

15

[31]

16

[8]

17

[32]

18

[33]

19

[6]

20

[34]

21

[10]

22

[35]

23

[36]

Y

N

?

Sequence generation

?

?

?

Y

?

Y

?

?

Y

?

?

?

Y

Y

?

?

Y

?

Y

?

Y

?

Y

9

0

14

Allocation concealment

?

?

Y

Y

?

?

?

?

Y

?

?

?

?

?

?

?

Y

?

?

?

?

?

Y

5

0

18

Appropriate blinding of participants

?

N

Y

N

?

?

?

Y

N

Y

?

?

?

?

?

?

Y

?

Y

?

?

N

Y

6

4

13

Appropriate blinding of outcome assessors

?

Y

Y

N

?

?

?

Y

?

Y

?

?

?

?

?

?

?

?

?

?

?

N

Y

5

2

16

Appropriate blinding of physician

?

?

Y

N

?

?

?

Y

?

Y

?

?

?

?

?

?

?

?

?

?

?

N

Y

4

2

17

Registration of loss to follow-up

Y

Y

?

?

Y

Y

?

?

Y

Y

Y

Y

Y

Y

Y

?

?

Y

?

Y

Y

Y

Y

16

0

7

Way missing values were dealt with

?

?

?

Y

?

?

?

?

Y

?

?

?

?

?

?

?

Y

Y

?

?

?

?

?

4

0

19

Compliance checked

Y

?

?

Y

Y

?

?

?

Y

?

?

Y

Y

Y

?

Y

?

Y

?

?

Y

?

Y

11

0

12

Selective reporting

?

?

?

?

?

N

?

?

?

?

?

?

?

?

?

?

?

?

?

?

?

?

?

0

1

22

Total times “Yes”

2

2

4

4

2

2

0

3

5

4

1

3

3

3

1

1

4

3

2

1

3

1

7

   

Overall score Y/N/?

                       

60

9

138

  1. Each trial could score “yes” for a low, “no” for a high and “?” for an uncertain risk of bias, respectively.
  2. The 9 items are based on a combination of the Cochrane approach to assess the risk of bias, combined with the validity checklist of Jadad et al. [17, 18].